Fulcrum Therapeutics
Patents, Design & Utilities

Last updated:

List of all Fulcrum Therapeutics patents 8 in total

Status Patent
Application
Utility: MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS External link
Filling date: 6 Sep 2025 Issue date: 26 May 2022
Application
Utility: P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD External link
Filling date: 6 Sep 2025 Issue date: 5 May 2022
Application
Utility: COMPOSITIONS AND METHODS FOR INCREASING FETAL HEMOGLOBIN AND TREATING SICKLE CELL DISEASE External link
Filling date: 6 Sep 2025 Issue date: 20 Jan 2022
Grant
Utility: Macrocyclic azolopyridine derivatives as EED and PRC2 modulators External link
Filling date: 6 Sep 2025 Issue date: 13 Apr 2021
Application
Utility: P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD External link
Filling date: 6 Sep 2025 Issue date: 10 Dec 2020
Application
Utility: MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS External link
Filling date: 6 Sep 2025 Issue date: 19 Nov 2020
Application
Utility: USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4 External link
Filling date: 6 Sep 2025 Issue date: 22 Oct 2020
Grant
Utility: P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD External link
Filling date: 6 Sep 2025 Issue date: 21 Jan 2020

Showing 1 to 8 of 8 patents.